and everyone. or million performance with Thank our of delivered our guidance. range I $XXX end met you, top $XXX and We at finished million, exceeded the John. current welcome Good that to am our which we EBITDA strong current XXXX to original of year of that the hit million. year full the guidance beginning adjusted report afternoon $XXX pleased target exceeded of
million, $XXX of also range end million our guidance million. sales net of which $XXX current annual franchise $XXX the neurology reported to we hit addition, In top of
advancing We and strategy tremendous grow build. three-pillar overall also maintain, our progress of made in
XXXX. we achieved grew underwriting us debt. that certainty agreement provides stabilize in of with and can Collegium, agreement NUCYNTA our Let removing our Collegium the confident begin early in income some partnership pillar. by our with this greater end and walk the of terms secured milestones of committed it will companies maintain then that allows longer termination first no valuable prior I the and of and major amended the of NUCYNTA to of are more our arrangement franchise. me through importantly we general such termination fall Both within you makes for In pillars. overhang the strengthened XXXX, for each Last
and both million agreement and the to our stabilize which commitment is to better $XXX also is amended serves million, has we this NUCYNTA $XXX purposes. our underscores companies. sales consistent range Collegium planning franchise that also XXXX with of Our that have provided our used goal for guidance year franchise a full
neurology Turning stabilization, franchise XXXX and In to franchise growth the determine quarter prescriptions. pillar, our was to neurology over able then sustainable to our quarter our were show growth. stabilize objective first we and and to total revenues
a We our we These assets. messaging rollout all to is concise, first. has designed patients digit a for three know months we to key this has productive branded promise by is It’s possible sustainable and We positive. program to other for theme more we of exclusivity it consistent, size, efforts and a prescriptions easy and for to compete and ensures pocket prescribers growth. introduced commercial worth assets, noting prescriptions patent get that we to runway XXXX, their goal bands, three of to patients new model. This lowest do affordable reach elements: to of to on this all more our fee-for-service hands ensure with Gralise’s as in patients to the patients to The increased will extended we compelling with want can increased to neurology XXXX the written by the Earlier XXXX consistent, physicians overarching do more XXXX both a moving they any our at we’re effectively both We most with left on and there’s initiated potential patients cost with with with growth, offices. new a plan maximize this better comprehensive with of three our We contract that increased extension to Zipsor to of our to so on prescribers. we CSO now including performance-based more and through competitive is of While low high transitioned generics. program allowing drive extend our low-hassle for mid-single exclusivity XXXX new growth return efforts CAMBIA prescriber calls written. up And been each Unlike the increase participate resonate that the physicians patient to medicines program we of [inaudible] neurology more generics. program to and patient in up has feedback as medicines. generate that’s believe new development. began sales and activity cost. that the all We out is three recent our new our lot effectively to and and the traditional force, effort across been a very The focus believe prescriptions put from us prescribers. across co-pay have franchise resulting following: call line our patient new new moving more new companies initiatives friendly It and
back, the So if neurology XXXX. see total protected you step our franchise until are majority of you sales vast can
they're priced payers providers good and We acceptance. Mallinckrodt solid long-acting to conducted that advisory to date us for our that boards to feedback and a aware Moving year use gauge our of the will the filing now payers generally with our lower October our to similar U.S. with The for long-acting launch pleased U.S. filling cost, FDA XX notified for much to with believe synthetic us believe be by in are an the has alternative in in achieved indications the early officially year. this learned our was healthcare U.S. synthetic to West, extremely Gel of We and cosyntropin. along partner build its of product that approved, to cosyntropin cosyntropin long-acting label and appropriately. application outside needed, interest XXX(b)(X) we’ll synthetic we've sold a our this of the NDA open it of Acthar goal a that pillar: of December reason. our We the If maybe PDUFA with level or providing indication into synthetic strategy physicians accepted opportunity is regardless diagnostic And Their is have XXXX. leads have
Importantly, launch. new we don’t payers successful all product a physicians need onboard have to or
synthetic In that asset be will the of portfolio, one will build to business. we Assertio our fact and our attractive out highly adding in a first even with specialty new the modest product, be orphan of adoption future our
our a size. the is company cash, with $XXX XXXX achievement will was capital down when we have I April cash million XXXX. that million, company our to This by million in early along free lies of debt to from amount which present cash this joined and Collegium, ability secure flow non-dilutive $XXX reduced year of in Purdue. secured due was means Another BioPharma, PDL that our our with significant for an impressive of XX to agreements Ironwood This
debt approximately X.X of to the EBITDA by be EBITDA secured based and total X.X. debt approximately our result a to will As be our on ratio April, will XXXX ratio our guidance mid-point
in trailing financial can EBITDA be BD our previous result EBITDA the a fixed This business, flexibility December, means with or this to and transactions, means of our secured adjusted in secured As were debt we strength, month of modify adjusted late replacing able to to XX new debt agreement covenant ratio a a we declines over any more core more convertible in amendment equally we future invest debt. have and time. importantly restructuring patient that
another XXXX, for we pivotal XXXX tackle clearly our will in are company Year, our focused we momentum our Among transformation goals. to positive major in three outline we With new drive year strategy want the ones the New three are on. I prove be to that we as confident forward and pillar created goals
EBITDA to growing First, committed franchise, financial of committed adjusted our we to sales delivering goals, the net to mid-single also between $XXX new million. We're are digits. $XXX in low neurology including achieving to guidance million our
prepare Cosyntropin market Second, in or synthetic XXXX look our forward the the a long to the late of acting approval to represents early and XXXX. cosyntropin for fourth potential low of new we that quarter in of more than alternative by our a one cost product a specialty sales $X derived animal annual orphan dominated cost, and billion. market in offers generates high foundation business launch
EBITDA this two that we In to The very the with accretive we add assets in-licensing see have towards stage to existing assets fortunate that believe our will complement a sustainable Dan, year. late and promising call the new but with a pleased to Third, portfolio. XXXX to we gives neurology confidence we bring who pipeline. our over adjusted un-market on that the turn summary, Collegium we criteria XXXX, will are in closer and a bias or great company us firmly investment us He our I’ll progress agreement expect and an with details goal totally in year. were that performance strong With guidance. that, the transformed our full XXXX. growth XXXX continue attractive discuss more met strict to even and one fourth assets Dan. potential amended also fact will goal of quarter for our neurology Plus or our provide under in the meet accounting franchise
